FDA Rejects Novocure Brain Metastasis Device
The agency issued a not approvable letter for Optune Mya, citing uncertainty about the degree of clinical benefit.
Updated on Nov. 9, 2026 in Cancer

The FDA issued a not approvable letter for Novocure's Optune Mya premarket application, which concerned adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. Novocure shares fell 2.4% to $12.96 in premarket trading on Nasdaq.
Why it matters
The FDA said uncertainty around the degree of clinical benefit prevented approval, though it did not raise safety concerns about the device. The decision leaves the treatment for this patient group without a clear path to U.S. authorization for now.
The figures come from FDA regulatory action and Nasdaq trading data, with Novocure shares down 19% over three months and up 2.7% year-to-date as of Friday's close. The FDA's specific clinical-benefit concerns are not quantified in the extraction, and it remains unclear what additional evidence would be required.
The players
Novocure
Novocure is a Swiss-based medical device company that develops Tumor Treating Fields therapies, including the Optune system, for cancer treatment.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for reviewing and approving medical devices and drugs for safety and effectiveness before they are marketed in the United States.
The details
Novocure received the not approvable letter from the FDA in response to its premarket application for Optune Mya. The company said it is evaluating the agency's feedback and plans to meet with the FDA to determine whether options exist that would support approval without additional clinical studies.
Timeline
Monday, November 9, 2026: Novocure announced the FDA's not approvable letter.
Friday prior to publication: Novocure shares closed, with three-month and year-to-date figures measured.
Health Landscape
Novocure's Tumor Treating Fields platform, which uses electric fields to disrupt cancer cell division, has been expanding from glioblastoma into other tumor indications. This FDA action marks a regulatory hurdle for that expansion into brain metastases, where the agency is requiring stronger evidence of clinical benefit.
Patients with brain metastases from non-small cell lung cancer should not expect Optune Mya to become available through U.S. approval in the near term. Anyone considering treatment options should discuss the current status of this device with their oncology team.
The takeaway
Regulatory decisions often hinge on the strength of clinical benefit evidence rather than safety alone, so patients and families should watch for the outcome of any follow-up FDA discussions. Asking a care team about approved options for brain metastases can help clarify what is currently available.
What happens next
Novocure plans to meet with the FDA to discuss whether approval could be supported without additional clinical studies, though there is no assurance these talks will lead to approval.
Further reading
For related coverage, explore Cancer news and research.










